Depressive states in the structure of postcovid syndrome: features and therapy

The article provides a review of the scientific literature devoted to postcoid conditions. The concept of postcovid syndrome, its structure, and epidemiology are disclosed. The article contains the results of 2 meetings of experts (psychiatrists, psychotherapists, neurologists) from different regions of Russia who had experience in providing care to persons with postkovid syndrome. Particular attention is paid to postcovid depression, its clinical characteristics, and the experience of therapy. It was noted that the severity of the post-coV syndrome did not depend on the severity of the infectious disease suffered. The leading variants of depressive syndromes observed in SARS-CoV-2 patients were: astheno-depressive, apato-depressive and anxious-depressive syndromes. Anhedonia, anxiety, cognitive disorders, insomnia, and hypochondria occupied a significant place in the structure of postcovid mental disorders. It is emphasized that persons with postcovid syndrome, as a rule, initially found themselves in the field of vision of internists, therefore, their training in the diagnosis of postcovid mental disorders is relevant. Clinical experience has demonstrated the feasibility of antidepressant therapy for postcovid depression and the high efficacy and safety, including the risk of drug interactions, of using vortioxetine, including prescribing the drug to the elderly and the somatically impaired. The article is illustrated with clinical examples.

1. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. «20 вопросов о «постковидном синдроме». [https://www.rospotrebnadzor.ru/]. Rospotrebnadzor; 2022. Доступно: https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=20293

2. Assessing the Global Burden of Post-COVID-19 Condition. Modeling the incidence of Post-COVID conditions worldwide based on real -world evidence and clinical literature review. IQVIA Institute for Human Data Science, December 2021.

3. Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2018;21(2):97-107. doi: 10.1093/ijnp/pyx070. PMID: 29053849; PMCID: PMC5793828.

4. Buttery S, Philip KEJ, Williams P, et al. Patient symptoms and experience following COVID-19: results from a UK-wide survey. BMJ Open Resp Res, 2021;8:e001075. doi:10.1136/ bmjresp-2021-001075.

5. Centers for Disease Control and Prevention (CDC). Post-COVID Conditions: Information for Healthcare Providers. US: CDC; 2021 [Updated 2021 Jul 09; cited 2021 Sep 06]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html

6. Davis HE, Assafa GS, McCorkella L et al. Characterizing long COVID in an international cohort:7 months of symptoms and their impact. EClinicalMedicine 38, 2021. DOI:10.1016/j.eclinm.2021.101019

7. Hampshire А, Trender W, Chamberlain SR et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021; 39. DOI: https://doi.org/10.1016/j.eclinm.2021.101044).

8. Kim Y, Bitna-Ha, Kim, SW et al. Post-acute COVID- 19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis 22, 93.2022. https://doi.org/10.1186/s12879-022-07062-6

9. Lopez-Leon S, Wegman-Ostrosky Т, Perelman С et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 11, 16144 (2021). https://doi.org/10.1038/s41598-021-95565-8.

10. National Institute for Health and Care excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. UK:NICE; 2021 Dec 18. [updated 2021 Nov 11; cited 2021 Aug 25]. Available from: https://www.nice.org.uk/guidance/ng188